ZA200800521B - A method for detecting peptide comprising a cross-<beta> structure - Google Patents

A method for detecting peptide comprising a cross-<beta> structure

Info

Publication number
ZA200800521B
ZA200800521B ZA200800521A ZA200800521A ZA200800521B ZA 200800521 B ZA200800521 B ZA 200800521B ZA 200800521 A ZA200800521 A ZA 200800521A ZA 200800521 A ZA200800521 A ZA 200800521A ZA 200800521 B ZA200800521 B ZA 200800521B
Authority
ZA
South Africa
Prior art keywords
beta
cross
detecting peptide
peptide
detecting
Prior art date
Application number
ZA200800521A
Inventor
Gebbink Martijn Frans Ben Gerard
Bouma Barend
Original Assignee
Crossbeta Biosciences Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crossbeta Biosciences Bv filed Critical Crossbeta Biosciences Bv
Publication of ZA200800521B publication Critical patent/ZA200800521B/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biophysics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
ZA200800521A 2005-07-13 2008-01-17 A method for detecting peptide comprising a cross-<beta> structure ZA200800521B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11/181,040 US8114832B2 (en) 2005-07-13 2005-07-13 Method for detecting and/or removing a protein comprising a cross-beta structure from a pharmaceutical composition

Publications (1)

Publication Number Publication Date
ZA200800521B true ZA200800521B (en) 2008-12-31

Family

ID=37441867

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200800521A ZA200800521B (en) 2005-07-13 2008-01-17 A method for detecting peptide comprising a cross-<beta> structure

Country Status (6)

Country Link
US (2) US8114832B2 (en)
EP (1) EP1910842A2 (en)
AU (1) AU2006267173A1 (en)
CA (1) CA2615025A1 (en)
WO (1) WO2007008069A2 (en)
ZA (1) ZA200800521B (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1820806A1 (en) * 2006-02-16 2007-08-22 Crossbeta Biosciences B.V. Affinity regions
EP1380290A1 (en) 2002-07-09 2004-01-14 Universitair Medisch Centrum Utrecht Cross-beta structure pathway and its therapeutic relevance
US20070003552A1 (en) * 2002-07-09 2007-01-04 Gebbink Martijn F B Cross-beta structure comprising amyloid binding proteins and methods for detection of the cross-beta structure, for modulating cross-beta structures fibril formation and for modulating cross-beta structure-mediated toxicity and method for interfering with blood coagulation
US20090202980A1 (en) * 2005-03-21 2009-08-13 Crossbeta Biosciences B.V. Cross-Beta Structure Comprising Amyloid Binding Proteins and Methods for Detection of the Cross-Beta Structure, for Modulating Cross-Beta Structures Fibril Formation and for Modulating Cross-Beta Structure-Mediated Toxicity and Method for Interfering With Blood Coagulation
BRPI0613525A2 (en) * 2005-07-13 2011-05-31 Crossbeta Biosciences Bv methods for producing an immunogenic composition, for enhancing the immunogenicity of a composition, for enhancing the immunogenicity of a vaccine composition, and for determining the amount of beta-cross structures in a vaccine composition, uses of beta-cross structures, and an immunogenic composition, subunit vaccine, and immunogenic composition
US8114832B2 (en) * 2005-07-13 2012-02-14 Crossbeta Biosciences B.V. Method for detecting and/or removing a protein comprising a cross-beta structure from a pharmaceutical composition
EP1910844B1 (en) * 2005-07-13 2012-04-18 Crossbeta Biosciences B.V. Cross-beta structure binding compounds
US20080249606A1 (en) * 2005-07-13 2008-10-09 Martijn Frans Ben Gerard Gebbink Methods for Determining the Effect of a Treatment on the Cross-Beta Structure Content of a Protein; Selection of Treatments and Uses Thereof
AU2007212812A1 (en) * 2006-02-09 2007-08-16 Biochromix Ab Methods for detection of pathogenic prion proteins associated with prion diseases, using conjugated polyelectrolytes
CA2645930A1 (en) * 2006-03-17 2007-09-27 Crossbeta Biosciences B.V. Methods of binding of cross-beta structures by chaperones
CN101948505A (en) * 2007-04-18 2011-01-19 比奥克罗密克斯有限公司 Use the protein of conjugated polyelectrolytes binding of pathological forms
US20100310461A1 (en) * 2007-04-18 2010-12-09 Biochromix Pharma Ab Binding of pathological forms of proteins using conjugated polyelectrolytes
US20100310462A1 (en) * 2007-04-18 2010-12-09 Biochromix Ab Binding of pathological forms of proteins using conjugated polyelectrolytes
CN101947235A (en) * 2007-04-18 2011-01-19 比奥克罗密克斯药业有限公司 The medical usage of conjugated polyelectrolytes
EP2236142A1 (en) * 2007-04-18 2010-10-06 Biochromix Pharma AB Medical use of conjugated polyelectrolytes
WO2008137571A1 (en) * 2007-05-01 2008-11-13 Florida Atlantic University Methods of treating neurodegenerative diseases
BRPI0812348B8 (en) * 2007-06-04 2021-05-25 Vib Vzw method for down-regulating or down-regulating the biological function of a protein, chimeric molecule, recombinant vector and method for isolating a protein from a sample
EP2058001A1 (en) * 2007-11-08 2009-05-13 Crossbeta Biosciences B.V. Enhancement of immunogenicity of antigens
EP2058000A1 (en) * 2007-11-08 2009-05-13 Crossbeta Biosciences B.V. Immunogenic compositions capable of activating T cells
US11851487B2 (en) * 2019-04-01 2023-12-26 Rensselaer Polytechnic Institute Methods and systems for detecting peptide aggregates

Family Cites Families (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5733524A (en) 1984-03-19 1998-03-31 The Picower Institute For Medical Research Methods and materials for the diagnosis and treatment of conditions such as stroke
US5869534A (en) 1992-05-21 1999-02-09 The Picower Institute For Medical Research Glycosylation of lipids and lipid-containing particles, and diagnostic and therapeutic methods and materials derived therefrom
US5733933A (en) 1984-03-19 1998-03-31 The Picower Institute For Medical Research Methods and materials for the diagnosis and treatment of conditions such as stroke
US5700447A (en) 1992-05-21 1997-12-23 The Picowder Institute For Medical Research Methods and materials for the diagnosis and treatment of conditions such as stroke
US5801200A (en) 1984-03-19 1998-09-01 The Picower Institute For Medical Research Methods and materials for the diagnosis and treatment of conditions such as stroke
ATE70301T1 (en) 1986-02-17 1991-12-15 Stichting Centraal Lab TISSUE PLASMINOGEN ACTIVATOR MUTANT, ENCODING RECOMBINANT GENETIC INFORMATION THEREOF AND METHODS FOR THE PRODUCTION OF SUCH MUTANTS, THEIR USE AND PHARMACEUTICAL COMPOSITIONS.
EP0319144A1 (en) 1987-11-06 1989-06-07 Asahi Kasei Kogyo Kabushiki Kaisha Adsorbent of beta 2-microglobulin
DE3853219T2 (en) 1987-11-20 1995-06-29 Kanegafuchi Chemical Ind Method of removing serum amyloid protein.
US5216127A (en) 1987-11-20 1993-06-01 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Adsorbent for serum amyloid protein
US5151082A (en) 1988-08-05 1992-09-29 Heathdyne, Inc. Apparatus and method for kidney dialysis using plasma in lieu of blood
CA1335361C (en) 1989-05-24 1995-04-25 Andrei Z. Budzynski Thrombus-targeted complexes of plasminogen activator and fibrin fragments
US5180615A (en) 1989-12-13 1993-01-19 W.R. Grace & Co.-Conn. Metallized bag for static protection of electronic components
US5591431A (en) 1990-03-09 1997-01-07 G.D. Searle & Co. Enhancement of clot lysis
US5753624A (en) 1990-04-27 1998-05-19 Milkhaus Laboratory, Inc. Materials and methods for treatment of plaquing disease
US5650418A (en) 1990-06-04 1997-07-22 Therapy 2000 Therapeutic lysine salt composition and method of use
US5278189A (en) 1990-06-04 1994-01-11 Rath Matthias W Prevention and treatment of occlusive cardiovascular disease with ascorbate and substances that inhibit the binding of lipoprotein (A)
US5230996A (en) 1990-06-04 1993-07-27 Therapy 2000 Use of ascorbate and tranexamic acid solution for organ and blood vessel treatment prior to transplantation
US5780587A (en) 1990-08-24 1998-07-14 President And Fellows Of Harvard College Compounds and methods for inhibiting β-protein filament formation and neurotoxicity
SE468881B (en) 1991-01-09 1993-04-05 Kabi Pharmacia Ab APPLICATION OF CERTAIN PHARMACEUTICALS FOR THE PREPARATION OF MEDICINAL PRODUCTS FOR TREATMENT OF ENDOTOXIN-INDEXED EFFECTS AND THE PREPARATION OF ENDOTOXINES FROM MISCELLANEOUS SOLUTIONS
US5221628A (en) 1991-03-19 1993-06-22 Northwestern University Binding of aggregated immunoglobulin or immune complexes by serum amyloid P component
US5276059A (en) 1992-07-10 1994-01-04 The United States Of America As Represented By The Department Of Health And Human Services Inhibition of diseases associated with amyloid formation
CA2101614A1 (en) 1992-07-30 1994-01-31 Shmuel Shaltiel Synthetic peptides derived from vitronectin and pharmaceutical compositions comprising them
US5958883A (en) 1992-09-23 1999-09-28 Board Of Regents Of The University Of Washington Office Of Technology Animal models of human amyloidoses
DE4242736A1 (en) 1992-12-17 1994-06-23 Behringwerke Ag Synthetic peptides, antibodies against them and their use
US5955343A (en) 1992-12-28 1999-09-21 Massachusetts Institute Of Technology Stable macroscopic membranes formed by self-assembly of amphiphilic peptides and uses therefor
US5750349A (en) 1993-01-25 1998-05-12 Takeda Chemical Industries Ltd. Antibodies to β-amyloids or their derivatives and use thereof
US5691135A (en) * 1993-01-26 1997-11-25 The Regents Of The University Of California Immunoglobulin superantigen binding to gp 120 from HIV
US5786327A (en) * 1993-03-12 1998-07-28 Gensci Regeneration Sciences Inc. Bone stimulating factor, methods of isolating same, and methods of increasing bone growth comprising administering same
US5449663A (en) 1993-06-11 1995-09-12 Bicher; Haim I. Antineoplastic compositions
JP3537440B2 (en) 1993-12-17 2004-06-14 持田製薬株式会社 Method for stabilizing soluble thrombomodulin for long-term storage
US6410598B1 (en) 1994-02-03 2002-06-25 Michael P. Vitek Compositions and methods for advanced glycosylation endproduct-mediated modulation of amyloidosis
JPH09511492A (en) 1994-02-03 1997-11-18 ザ ピコワー インスティテュート フォア メディカル リサーチ Compositions and methods for advanced glycosylation end product mediated modulation of amyloidosis
KR0163563B1 (en) 1994-03-23 1998-12-01 김종인 Topical drug in combination for treatment of skin lesions
US5786324A (en) 1994-03-24 1998-07-28 Regents Of The University Of Minnesota Synthetic peptides with bactericidal activity and endotoxin neutralizing activity for gram negative bacteria and methods for their use
US6136548A (en) 1994-11-22 2000-10-24 Rutgers, The State University Of New Jersey Methods for identifying useful T-PA mutant derivatives for treatment of vascular hemorrhaging
US5589154A (en) 1994-11-22 1996-12-31 Rutgers, The State University Of New Jersey Methods for the prevention or treatment of vascular hemorrhaging and Alzheimer's disease
US5888774A (en) 1994-12-19 1999-03-30 Cangene Corporation Recombinant DNA molecules and expression vectors for erythropoietin
US6319498B1 (en) * 1995-03-14 2001-11-20 Praecis Pharmaceuticals Incorporated Modulators of amyloid aggregation
US5817626A (en) 1995-03-14 1998-10-06 Praecis Pharmaceuticals Incorporated Modulators of beta-amyloid peptide aggregation
US5854215A (en) 1995-03-14 1998-12-29 Praecis Pharmaceuticals Incorporated Modulators of β-amyloid peptide aggregation
US5948763A (en) 1995-06-07 1999-09-07 New York University Peptides and pharmaceutical compositions thereof for treatment of disorders or diseases associated with abnormal protein folding into amyloid or amyloid-like deposits
US6436969B1 (en) 1995-09-12 2002-08-20 Kansas University Medical Center Research Institute Inc. Dialysis solutions and methods
AU7253596A (en) 1995-10-02 1997-04-28 Mohammad W. Katoot Biologically-active polymers
US5985242A (en) 1995-10-27 1999-11-16 Praecis Pharmaceuticals, Inc. Modulators of β-amyloid peptide aggregation comprising D-amino acids
US6310046B1 (en) 1995-11-17 2001-10-30 The United States Of America As Represented By The Secretary Of The Army Sequestrin of Plasmodium falciparum
AU1529297A (en) 1996-01-24 1997-08-20 Warner-Lambert Company Method of imaging amyloid deposits
US5785187A (en) * 1996-04-29 1998-07-28 Lipman; Daniel Mechandising display assembly
US6034211A (en) 1996-06-03 2000-03-07 Kelly; Jeffery W. β-sheet nucleating peptidomimetics
US6929807B1 (en) 1996-08-09 2005-08-16 Mannatech, Inc. Compositions of plant carbohydrates as dietary supplements
US6689275B1 (en) * 1996-12-31 2004-02-10 Ajay Gupta Method and pharmaceutical composition for replacing iron losses in dialysis patients
US6372473B1 (en) 1997-05-28 2002-04-16 Human Genome Sciences, Inc. Tissue plasminogen activator-like protease
US20020122807A1 (en) 1998-07-07 2002-09-05 Dan Michael D. Antigen binding fragments, designated 4B5, that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers
DE19735902A1 (en) 1997-08-19 1999-02-25 Imtec Immundiagnostika Gmbh New selective adsorbent carrying peptide(s) that mimic complement C1q
ATE241365T1 (en) 1997-08-28 2003-06-15 Univ Washington PREPARATIONS CONTAINING SACCHARIDE FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND OTHER AMYLOIDOSES
JP2001521002A (en) 1997-10-24 2001-11-06 コーネル リサーチ ファンデーション インク． Nutritional supplements for brain metabolic dysfunction
JP4037525B2 (en) 1998-03-25 2008-01-23 生化学工業株式会社 New antibacterial peptide
US7041287B2 (en) 1998-05-21 2006-05-09 Trustees Of The University Of Pennsylvania Compositions and methods for selective dissolution of nascent intravascular blood clots
WO2000009562A1 (en) 1998-08-12 2000-02-24 The New York Blood Center, Inc. Novel cleaved fragments of fibrinogen
WO2000018398A1 (en) 1998-09-25 2000-04-06 Sunol Molecular Corporation Pharmaceutically active compounds and methods of use thereof
IN190822B (en) 1998-12-24 2003-08-23 Council Scient Ind Res
US6242473B1 (en) 1999-01-08 2001-06-05 Maxim Pharmaceuticals, Inc. Treatment and prevention of reactive oxygen metabolite-mediated cellular damage
US6161547A (en) 1999-01-15 2000-12-19 Coaxia, Inc. Medical device for flow augmentation in patients with occlusive cerebrovascular disease and methods of use
DE60026501T2 (en) 1999-04-30 2006-08-10 Matsumoto, Akira HUMAN BRAIN SPECIFIC CARBOXYPEPTIDASE B
AT500670A1 (en) 1999-05-19 2006-02-15 Bio & Bio Licensing Sa DRUGS FOR LOCAL APPLICATION
DK1409654T3 (en) 1999-06-16 2008-12-08 Boston Biomedical Res Inst Immunological control of beta-amyloid levels in vivo
GB9917725D0 (en) 1999-07-28 1999-09-29 Medical Res Council Peptides
WO2001012598A2 (en) 1999-08-13 2001-02-22 The Trustees Of Columbia University In The City Of New York METHODS OF INHIBITING BINDING OF β-SHEET FIBRIL TO RAGE AND CONSEQUENCES THEREOF
US20040013647A1 (en) 1999-09-03 2004-01-22 Ramot At Tel-Aviv University Ltd. Methods and compositions for treating a plaque-forming disease
KR100681632B1 (en) 1999-09-14 2007-02-09 메이지 세이카 가이샤 리미티드 Phosphonic acid derivatives having carboxypeptidase B inhibitory activity
US6399314B1 (en) 1999-12-29 2002-06-04 American Cyanamid Company Methods of detection of amyloidogenic proteins
EP1252181B1 (en) 2000-01-20 2006-01-18 Regents Of The University Of Minnesota Peptides with antibacterial activity
AU3173301A (en) 2000-02-11 2001-08-20 European Molecular Biology Laboratory Methods and compositions for treatment of alzheimer's disease by enhancing plasmin or plasmin-like activity
JP5025871B2 (en) 2000-02-21 2012-09-12 エイチ．リュンドベック エイ／エス A novel method for down-regulation of amyloid
KR100879810B1 (en) 2000-02-21 2009-01-22 하. 룬드벡 아크티에셀스카브 Novel method for down-regulation of amyloid
EP1130031A1 (en) 2000-02-25 2001-09-05 Universitair Medisch Centrum Utrecht Method for inhibiting angiogenesis using molecules that enhance plasmin formation or prolong plasmin activity
WO2001070762A2 (en) 2000-03-21 2001-09-27 Research Foundation Of State University Of New York Adsorption of polyampholytes to charged surfaces and assays incorporating same
RU2324686C2 (en) 2000-08-24 2008-05-20 Юнивесити Оф Питсбэг AMYLOID-BINDING THIOFLAVIN DERIVATIVES, METHOD OF in vivo DETECTION OF AMYLOID DEPOSIT AND METHOD OF DIAGNOSTICS OF ALZHEIMER'S DISEASE
US7270800B2 (en) 2000-08-24 2007-09-18 University Of Pittsburgh Thioflavin derivatives for use in antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition
EP1186299A1 (en) 2000-09-12 2002-03-13 Universitair Medisch Centrum Utrecht The diagnosis, prevention, and/or succesful treatment of atherosclerosis, infectious diseases, and disturbances in the immune system
DE60032250T2 (en) 2000-12-28 2007-03-15 Biomay Produktions- Und Handels-Aktiengesellschaft Treatment of allergies
WO2002099098A1 (en) 2001-04-04 2002-12-12 American Diagnostica, Inc Method of preparation of stabilized thrombin-activatable fibrinolysis inhibitor (tafi) and methods of use thereof
AU2002320045B2 (en) 2001-05-31 2008-05-08 Adlyfe, Inc. Misfolded protein sensor method
US6960465B1 (en) * 2001-06-27 2005-11-01 Northwestern University Increased cell resistance to toxic organic substances
US6737401B2 (en) 2001-06-28 2004-05-18 Metronic Minimed, Inc. Methods of evaluating protein formulation stability and surfactant-stabilized insulin formulations derived therefrom
AU2002312566A1 (en) 2001-07-09 2003-01-29 Elan Pharmaceuticals, Inc. Methods of inhibiting amyloid toxicity
JP2003024080A (en) * 2001-07-19 2003-01-28 Univ Tokyo Protein inducing p53-dependent apoptosis and method for screening apoptosis controlling agent
GB0202275D0 (en) 2002-01-31 2002-03-20 Hansa Medica Ab Peptide
EP1820806A1 (en) 2006-02-16 2007-08-22 Crossbeta Biosciences B.V. Affinity regions
EP1478931B2 (en) 2002-02-28 2018-11-07 Microsens Biophage Limited Binding of pathological forms of prion proteins
KR100518152B1 (en) * 2002-05-09 2005-09-29 메디제네스(주) A Pharmaceutical Composition for Treatment of Wounds Containing Blood Plasma or Serum
US20070003552A1 (en) 2002-07-09 2007-01-04 Gebbink Martijn F B Cross-beta structure comprising amyloid binding proteins and methods for detection of the cross-beta structure, for modulating cross-beta structures fibril formation and for modulating cross-beta structure-mediated toxicity and method for interfering with blood coagulation
EP1380290A1 (en) 2002-07-09 2004-01-14 Universitair Medisch Centrum Utrecht Cross-beta structure pathway and its therapeutic relevance
US20050142611A1 (en) * 2002-09-30 2005-06-30 Auburn University Method of isolation and self-assembly of small protein particles from blood and other biological materials
US7470667B2 (en) * 2002-12-05 2008-12-30 Medgenn (Hong Kong) Ltd Methods of treating cancer using a modified endostatin protein
EP1449536A1 (en) * 2003-02-14 2004-08-25 Prionics AG Prion proteins (PrP) as therapeutic agents for the treatment of AP-1 associated diseases
US7172875B2 (en) 2003-02-18 2007-02-06 The Ohio State University Research Foundation Identifying inhibitors of intracellular protein fibrillization
EP3192872A1 (en) 2003-08-26 2017-07-19 The Regents of the University of Colorado, a body corporate Inhibitors of serine protease activity and their use in methods and compositions for treatment of bacterial infections
US7427659B2 (en) 2003-10-24 2008-09-23 Amgen Inc. Process for purifying proteins in a hydrophobic interaction chromatography flow-through fraction
WO2006006172A2 (en) 2004-07-15 2006-01-19 Ramot At Tel Aviv University Ltd. Use of anti-amyloid agents for treating and typing pathogen infections
JP2008531553A (en) 2005-02-25 2008-08-14 メディジーンズ カンパニー リミテッド Pharmaceutical composition for the treatment of Avellino corneal dystrophy comprising plasma or serum
EP1704867A1 (en) 2005-03-18 2006-09-27 Crossbeta Biosciences B.V. Cross-beta structures on microbial organisms
US20090202980A1 (en) 2005-03-21 2009-08-13 Crossbeta Biosciences B.V. Cross-Beta Structure Comprising Amyloid Binding Proteins and Methods for Detection of the Cross-Beta Structure, for Modulating Cross-Beta Structures Fibril Formation and for Modulating Cross-Beta Structure-Mediated Toxicity and Method for Interfering With Blood Coagulation
EP1910844B1 (en) 2005-07-13 2012-04-18 Crossbeta Biosciences B.V. Cross-beta structure binding compounds
BRPI0613525A2 (en) 2005-07-13 2011-05-31 Crossbeta Biosciences Bv methods for producing an immunogenic composition, for enhancing the immunogenicity of a composition, for enhancing the immunogenicity of a vaccine composition, and for determining the amount of beta-cross structures in a vaccine composition, uses of beta-cross structures, and an immunogenic composition, subunit vaccine, and immunogenic composition
US20070015133A1 (en) 2005-07-13 2007-01-18 Umc Utrecht Holding B.V. Method for detecting and/or removing protein and/or peptide comprising a cross-beta structure from an aqueous solution comprising a protein
US8114832B2 (en) 2005-07-13 2012-02-14 Crossbeta Biosciences B.V. Method for detecting and/or removing a protein comprising a cross-beta structure from a pharmaceutical composition
US20080249606A1 (en) 2005-07-13 2008-10-09 Martijn Frans Ben Gerard Gebbink Methods for Determining the Effect of a Treatment on the Cross-Beta Structure Content of a Protein; Selection of Treatments and Uses Thereof
JP2009504636A (en) 2005-08-11 2009-02-05 メディジーンズ カンパニー リミテッド Pharmaceutical composition for treatment of nerve injury comprising plasma or serum
US8543424B2 (en) 2005-12-30 2013-09-24 Darryl Mark Hunsaker Vehicle insurance status display system
CA2645930A1 (en) 2006-03-17 2007-09-27 Crossbeta Biosciences B.V. Methods of binding of cross-beta structures by chaperones
US8071670B2 (en) * 2006-05-11 2011-12-06 Akzo Nobel Chemicals International B.V. Aqueous dispersions of polyvinylacetate and silica, processes for preparing the same, uses therefor and substrates coated and/or bonded therewith
HUE030269T2 (en) * 2006-06-26 2017-04-28 Macrogenics Inc Fc riib-specific antibodies and methods of use thereof
EP2058001A1 (en) 2007-11-08 2009-05-13 Crossbeta Biosciences B.V. Enhancement of immunogenicity of antigens
EP2058000A1 (en) * 2007-11-08 2009-05-13 Crossbeta Biosciences B.V. Immunogenic compositions capable of activating T cells

Also Published As

Publication number Publication date
US20070015206A1 (en) 2007-01-18
WO2007008069A3 (en) 2007-05-18
US8114832B2 (en) 2012-02-14
WO2007008069A2 (en) 2007-01-18
CA2615025A1 (en) 2007-01-18
EP1910842A2 (en) 2008-04-16
AU2006267173A1 (en) 2007-01-18
US20080207488A1 (en) 2008-08-28

Similar Documents

Publication Publication Date Title
ZA200800521B (en) A method for detecting peptide comprising a cross-&lt;beta&gt; structure
ZA200800524B (en) Method for detecting peptides comprising a cross-beta structure
EP1745150A4 (en) Method for detecting ncrna
GB2418282B (en) System for detecting a rollover
EP1924146A4 (en) A method for cell implantation
EP1945753A4 (en) Cassette for sample preparation
PL2423315T3 (en) A method for achieving improved polypeptide expression
GB0815478D0 (en) System for searching
GB0622294D0 (en) A cooling system for superconducting mgnets
GB0524887D0 (en) An arrangement for detecting a crash
EP1858537A4 (en) Prion-specific peptide reagents
IL192459A0 (en) Method for detecting alkylating agents
GB0610470D0 (en) A clamping structure for a handled tool
EP1710483A4 (en) Flare-shaped end structure for tube
EP1942893A4 (en) Piperidine glycine transporter inhibitors
GB0904267D0 (en) Method for cell analysis
EP1972597A4 (en) A method for storing gas
IL197979A0 (en) Method for peptide synthesis
EP1860491A4 (en) Method for manufacturing a periodically-poled structure
EP1931787A4 (en) System for detecting protein-protein interactions
GB0406953D0 (en) Method for preparing a sample
GB0804928D0 (en) System for evaluating a parts carrier
EP2077331A4 (en) METHOD FOR EVALUATING COMPOUND USING PKC-iota
GB0518299D0 (en) Clamping unit for a stairway
TWI317973B (en) Sawing method for a wafer